AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Akums Drugs and Pharmaceuticals has disclosed receiving an ESG rating score of 63 for Financial Year 2024-25 from NSE Sustainability Ratings & Analytics Limited, a subsidiary of NSE Indices Limited. The rating was assigned on 7th May, 2026 and disclosed on 8th May, 2026. Notably, the company did not engage NSE Sustainability for this rating — it was voluntarily assigned by NSE Sustainability purely on the basis of publicly available information. The disclosure is made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
A score of 63 provides a baseline ESG benchmark, but without peer comparison or scale context, the exact impact on investor sentiment remains unclear. The company's prompt voluntary disclosure reflects transparency in governance practices.